Prescriptions for weight loss and diabetes drugs are rising across the United States, causing a big boom in business for two pharmaceutical companies.

Last week Novo Nordisk, the makers of Ozempic and Wegovy, reported a 29% increase in sales.

Eli Lilly, the company behind Mounjaro, reported a 37% increase.

Both Ozempic and Mounjaro are prescription medications designed for adults with diabetes. Wegovy is used as an obesity treatment.

While the medicines have proven effective for weight loss, one study suggests that people taking the drugs may be at a higher risk for serious digestive problems.